Tag : ASTHMA

CONFERENCE UPDATE

From SABA reliance to ICS-first: Malaysia’s 2024 CPG ushers in a new era of asthma control
Malaysia’s 2024 Asthma Clinical Practice Guidelines (CPG) moves beyond short-acting β2-agonist (SABA)-only treatment, introducing inhaled corticosteroid (ICS)-based regimens from the earliest steps, phenotype/endotype-driven biologic algorithms, and system-level reforms to advance personalized asthma care

Dr. Andrea Ban Yu Lin

Associate Professor, Senior Consultant Physician and Pulmonologist, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia (HCTM-UKM), Kuala Lumpur, Malaysia
EXPERT INSIGHT

Beyond breathlessness: The evolving landscape of ILD management
Dr. Syazatul Syakirin Sirol Aflah

Consultant Respiratory Physician, Institut Perubatan Respiratori (IPR), Kuala Lumpur, Malaysia
CONFERENCE UPDATE

Tezepelumab’s impact on activity levels in patients with severe, uncontrolled asthma and CRSwNP: Post-hoc analysis of the phase 3 NAVIGATOR study
Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) can significantly limit patients' activity levels. This post hoc analysis of the phase 3 NAVIGATOR study assessed the impact of tezepelumab on activity-related items within the Asthma Quality of Life Questionnaire
CONFERENCE UPDATE

Improving asthma remission with benralizumab in real-world asthma patients in the US: Results from the ZEPHYR-4 study
The anti-interleukin-5 receptor α (anti-IL-5α) monoclonal antibody (mAb), benralizumab, had been approved for the treatment of severe eosinophilic asthma offering significant improvements in exacerbation rates, maintenance oral corticosteroid (mOCS) use, and other asthma outcomes in phase 3 clinical trials. Although benralizumab has achieved asthma remission in clinical trials and non-United States (US) populations, real-world data within the US assessing similar outcomes remained limited.
INFOGRAPHICS

Urine test to identify and verify a patient’s type of asthma